SCHEMBL29327971

SCHEMBL29327971

CCc1ccc(-c2cc3ccc(NC(=O)c4cc(C#N)ncc4S(C)(=O)=O)cc3cn2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ PPARG P37231 1/20 0.39
▸ KDR P35968 3/20 0.37
▸ ATR Q13535 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ MAPT P10636 4/20 0.36
▸ MITF O75030 1/20 0.36
▸ S1PR4 O95977 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ PAX8 Q06710 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ TLR9 Q9NR96 1/20 0.36
▸ TP53 P04637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327967 0.97 NPC1 (0.40) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327877 0.88 PPARG (0.48) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327944 0.86 ATR (0.40) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327871 0.84 PPARG (0.48) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327978 0.83 HDAC6 (0.47) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327941 0.83 ATR (0.40) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327992 0.83 PPARG (0.44) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327911 0.82 PPARG (0.46) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327980 0.81 MAPT (0.53) NPC1ALDH1A1HTTMEN1KMT2A
SCHEMBL29327747 0.81 PPARG (0.62) NPC1MEN1KMT2APPARGRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD NPC1 695/4885ALDH1A1 1367/4885HTT 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback